ArticleJournal of neurology2026
Fifteen years of autoimmune encephalitis in Denmark: incidence, epidemiology, and trends in treatment.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Term Outcomes in Autoimmune Encephalitis: A Nationwide, Clinical Study in Denmark.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionDespite increasing awareness of autoimmune encephalitis (AE), real-world, population-based epidemiological data are scarce. Using 15 years of nationwide, centralized testing data, we aimed to (1) characterize all Danish patients with neuronal cell-surface antibodies (NSAbs), GAD65, and GFAP; (2) estimate AE incidence in Denmark; and (3) assess temporal trends in treatment strategies.
methodsNationwide testing data from 2009 to 2023 were obtained from the Danish centralized antibody test center, and the medical records for antibody-positive patients were reviewed. National and regional incidence rates were calculated using census data, and trends in testing, incidence, and treatment were analyzed.
resultsA total of 198 patients were included. The most prevalent antibody was NMDAR (n = 79), followed by LGI1 (n = 37), GAD65 (n = 20), and CASPR2 (n = 19). The national average crude incidence rate (IR) in 2019-2023 was 2.8 cases per million person-years. Incidence increased by 10% annually during the study period (IRR 1.10, 95% CI 1.04-1.17, P = 0.001). The highest regional IR was observed in the region hosting the national testing center. Second-line treatment in NMDARE increased from 24% in 2009-2013 to 48% in 2019-2023. In contrast, use of steroid-sparing therapy declined from 41 to 26% in NMDARE and from 39 to 0% in LGI1. DISCUSSION: In this nationwide cohort, Danish AE patients were comparable to previously reported cohorts and incidence estimates were similar to those reported in other national studies. Higher incidence in the testing region suggests that local expertise improves case ascertainment. Treatment patterns evolved over time, likely reflecting increasing clinical experience with AE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.